Abstract: The present invention relates to a method for labeling or targeting cells whose plasma membrane has lost integrity, such as dead cells, such as for discriminating between live cells and cells whose plasma membrane has lost integrity; to an embodiment of the method for determining one or more values of one or more parameters of cells of a biological sample; to use of the method in an assay for screening drugs for therapy such as cancer therapy; to use of the method to monitor and/or determine the effectiveness of a therapy; to an assay kit; to a complex; to the complex for use as a medicament; to the complex for use in treatment of cancer(s) and/or plaque(s) and/or regeneration and/or supporting the immune system; and, to a dead cell.

Abstract: The invention relates to a shaped detergent product comprising 10-100 wt. % of a solid amorphous phase and 0-90 wt. % of one or more other solid phases, said solid amorphous phase comprising: 25-88 wt. % free acid equivalent of aminopolycarboxylate; 10-60 wt. % free acid equivalent of an acid, said acid not being an am inopolycarboxylate; 2-30 wt. % water; wherein the shaped detergent product contains at least 0.5 wt. % surfactant.

Abstract: A plasma etching method includes a physisorption step for causing an adsorbate that is based on first processing gas to be physisorbed onto a film to be etched, while cooling an object to be processed on which the film to be etched is provided; and an etching step for etching the film to be etched by causing the adsorbate to react with the film to be etched, using the plasma of second processing gas.

Abstract: A method for treating neurodegenerative disease in a subject in need thereof by administering to the subject an effective amount of a Nedd4 activator as described herein.

Abstract: A shaped detergent product comprising 10 to 100 wt. % of a first solid phase and 0 to 90 wt. % of one or more other phases, said first solid phase comprising: a) non-crystalline chiral aminopolycarboxylate; b) non-crystalline organic acid other than component a); c) at most 30 wt. % water; d) at most 50 wt. % of non-crystalline water-soluble component other than component a) or component b); e) at most 20 wt. % of homogeneously dispersed crystalline material; wherein the combination of the components a), b) and c) is present in the first solid phase in a concentration of at least 35 wt. % of the total weight of said solid phase; and wherein components a), b) and c) are present in the solid phase in a ratio of from 25 to 88 parts by weight of free acid equivalent of component a): from 10 to 60 parts by weight of free acid equivalent of component b) : from 2 to 30 parts by weight of component c); and wherein the shaped detergent product comprises at least 0.5 wt. % surfactant.

Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.

Abstract: A method of supplying and replenishing a laundry dosing system with one or more reservoirs providing stocks of components for laundry includes monitoring consumption of each of the components in the one or more reservoirs; automatically determining when each one or more reservoirs need replenishment from the monitoring; and replenishing one or more components in response to a monitoring result.

Abstract: Frozen confection composition comprising from 0 wt % to 5 wt % fat, from 0 wt % to 10 wt % protein, a fat to protein ratio of less than 1:1 and an emulsifier; wherein the fat droplets of the homogenised pre-mix of the frozen confection have an average droplet size d (3,2) of below 0.6 micron, and significantly reduced shrinkage of the product is observed on heat shock testing of the frozen confection product.

Abstract: Methods for treating a renal cell carcinoma with an improved combination of lenvatinib or a pharmaceutically acceptable salt thereof and everolimus are provided. These methods further comprises adjusting the dosages of lenvatinib during the onset of adverse effects to lead to improved treatment methods for human subjects with renal cell carcinoma. Particularly useful dosages and dose modifications upon the occurrence of adverse events are also provided.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.

Abstract: Disclosed is a composition including (per 100% weight): a) 90 wt.-% to 99.0 wt.-% water including, in dissolved form, 0.002 mol/L to 0.1 mol/L of at least one salt of ammonium cation or of a monovalent or multivalent metal cation with an organic or inorganic anion; b) 0.5 wt.-% to 5 wt.-% of a crosslinked anionic polyelectrolyte; and c) 0.5 wt.-% to 5 wt.-% of a compound having formula (II): R1—(O—CH2—CH2)p—OH (II), where the weight ratio of the crosslinked anionic polyelectrolyte to the compound of formula (II) is greater than or equal to 0.2 and less than or equal to 2.0, and the molar ratio of the compound of formula (II) to the salt greater than or equal to 0.05 and less than or equal to 1. Also disclosed is a composition in cosmetics and a method for lightening the thickened salt-rich composition.

Abstract: A method for decoding a data stream carried by a modulated signal includes receiving the modulated signal. The modulated signal is modulated according to a protocol belonging to a group of protocols including at least three protocols. The method further includes extracting a clock signal from the received modulated signal, detecting the protocol, and decoding the data stream according to the detected protocol using the extracted clock signal.

Abstract: A method of connecting a fine wire to an ultrafine wire, the fine wire exhibiting a first cross-section and the ultrafine wire exhibiting a second cross-section, the second cross-section smaller than the first cross-section, the method constituted of: providing an uninsulated portion of the fine wire exhibiting a flat surface; depositing a conductive material on the flat surface of the provided uninsulated portion of the fine wire; providing an uninsulated portion of the ultrafine wire; and bonding the provided uninsulated portion of the ultrafine wire to the deposited conductive material on the flat surface of the provided uninsulated portion of the fine wire by thermocompression.

Abstract: Machine and method for producing electronic-cigarette cartridges; being provided: a fill conveyor which feeds bottom shells of the cartridges along a fill path; a filling device located along the fill path to feed a measure of a liquid substance downwards into each bottom shell; an assembly conveyor which feeds bottom shells along an assembly path; a transfer station where the bottom shells are transferred from the fill conveyor to the assembly conveyor; and at least a first assembly device located along the assembly path to fit each bottom shell with a corresponding top cap.

Abstract: At least one of the embodiments described herein relate generally to a method of obtaining metadata for content stored in a first repository. The method may be performed at a second repository, and may include the acts of: identifying a content object stored in the first repository, the content object including learning content usable in an electronic educational system to provide electronic learning; identifying metadata for the content object stored in the first repository, the metadata associated with the learning content of the content object; retrieving the metadata associated with the learning content from the first repository; and storing a harvested content object corresponding to the content object. The harvested content object may includes the metadata associated with the learning content of the content object stored in the first repository.

Abstract: A single player vertical roulette mechanism is directed that includes a stand, a wheel and a motor. The wheel is configured to be mounted to the stand and rotate relative to the stand. The wheel includes a plurality of numbers corresponding to a roulette wheel. The motor is affixed to the stand and configured to rotate the wheel. A roulette ball is also fixedly mounted to the stand. A plurality of lights are fixedly mounted to the stand between the stand and the wheel. The plurality of lights illuminate the wheel so the numbers are visible to a player of the vertical roulette mechanism. A seat for a single player may also be connected to the stand enabling the roulette mechanism to be substituted for a traditional slot machine cabinet.